GlassScriptPhysician profile
Kitzia Rooks
NPI 1255949947
$619.24
in general payments reported to CMS, 2019-2025
12 companies · $40.26 in 2025
The $40.26 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $67.99 · 2023: $17.18 · 2024: $184 · 2025: $40.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $197.55 | 2021 | |
| Jazz Pharmaceuticals INC. | $112.55 | 2021 | |
| Daiichi Sankyo INC. | $67.33 | 2024-2025 | Injectafer |
| Eisai INC. | $54.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $47.83 | 2022 | |
| Lilly USA, LLC | $27.99 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $21.76 | 2024 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $20.16 | 2022 | |
| Glaxosmithkline, LLC. | $19.89 | 2024 | Nucala |
| Biogen, INC. | $18.70 | 2024 | Leqembi |
| Tg Therapeutics, INC. | $17.50 | 2024 | |
| Abbvie INC. | $13.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kitzia Rooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.